FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and can be used in medicine. Invention discloses a new peptide analogue of Exenatide. In comparison with the natural hormone GLP1 and exenatide, the analogue according to the present invention has an increased half-life of the subject.
EFFECT: invention can be used in treating diseases associated with disorders of biological function of hormone GLP-1, in particular in treating metabolic diseases, for example diabetes (type I or II), dyslipidemia, impaired glucose tolerance, etc.
6 cl, 4 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PRODUCING PEPTIDE EXENATIDE | 2011 |
|
RU2458066C1 |
| GLYCATED PEPTIDE GLP-1 | 2009 |
|
RU2543157C2 |
| GLP-1 PEPTIDE HAVING ATTACHED OLIGOSACCHARIDE CHAIN | 2008 |
|
RU2539829C2 |
| GLP-1 ANALOGUE DERIVATIVE OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS AND THEREOF APPLICATION | 2010 |
|
RU2565536C2 |
| SITE-SPECIFIC MONOPHYLATED ANALYGES OF EXCENDIN AND THE METHOD OF THEIR PRODUCTION | 2012 |
|
RU2625015C2 |
| PEPTIDE FOR MEDICAL TREATMENT OF PANCREATIC DIABETES OF 2ND TYPE AND ITS COMPLICATIONS | 2014 |
|
RU2573933C1 |
| PROCESS FOR PREPARATION OF GLYCOPEPTIDE HAVING SIALYLATED SUGAR CHAIN, AND METHOD FOR PRODUCING SIALYL GLYCOASPARAGINE | 2012 |
|
RU2586524C2 |
| MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
| PEPTIDE VECTORS | 2004 |
|
RU2361876C2 |
| NEW COMPOSITIONS OF EXENDINE AGONISTS AND METHODS OF THEIR ADMINISTRATION | 2000 |
|
RU2242244C2 |
